Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

572
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
572
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

995
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
995
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

428
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
428
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

255
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
255
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.8K
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

111
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preferential age-related striatal volume preservation in cervical dystonia.

Journal of neurology·2026
Same author

Study of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's sisease.

Brain : a journal of neurology·2026
Same author

Large-scale genetic characterization of Parkinson's disease in the African and African admixed populations.

Brain : a journal of neurology·2025
Same author

Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth.

Scientific reports·2025
Same author

CHD8-related neurodevelopmental disorder with non-epileptic myoclonus in an adult.

Epileptic disorders : international epilepsy journal with videotape·2025
Same author

Thalamic and Visual Network Dysfunction Relates to Tremor Response in Thalamic Deep Brain Stimulation.

Tremor and other hyperkinetic movements (New York, N.Y.)·2025

Related Experiment Video

Updated: Oct 30, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.7K

Managing Advanced Parkinson Disease.

Helen Hwang1, Scott A Norris1,2

  • 1Department of Neurology, 7548Washington University School of Medicine, St Louis, MO, USA.

Journal of Geriatric Psychiatry and Neurology
|July 5, 2021
PubMed
Summary
This summary is machine-generated.

Managing advanced Parkinson disease (PD) requires balancing motor symptoms, non-motor features, and medication side effects. Focus shifts towards improving quality of life with reduced medication and increased non-pharmacologic strategies.

Keywords:
advanced Parkinson’s diseasemotor fluctuationsnon-motor symptoms

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.5K

Related Experiment Videos

Last Updated: Oct 30, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.7K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.5K

Area of Science:

  • Neurology
  • Geriatrics
  • Movement Disorders

Background:

  • Advanced Parkinson disease (PD) presents complex challenges including motor fluctuations and functional decline.
  • Non-motor symptoms and adverse drug effects complicate management, impacting patient quality of life.
  • Current therapeutic strategies often struggle to balance motor symptom control with overall well-being.

Purpose of the Study:

  • To emphasize management strategies for advanced Parkinson disease.
  • To highlight the critical need for balancing therapeutic contributions against disease progression.
  • To guide clinicians in recognizing inflection points for adjusting treatment plans.

Main Methods:

  • Review and synthesis of current literature on advanced PD management.
  • Focus on clinical decision-making regarding pharmacologic and non-pharmacologic interventions.
  • Emphasis on a multidisciplinary approach tailored to individual patient needs.

Main Results:

  • Management decisions in advanced PD must weigh disease progression against therapeutic benefits.
  • Identifying inflection points prompts consideration of reduced medication burden.
  • Increased reliance on non-pharmacologic strategies is often beneficial.

Conclusions:

  • Successful management of advanced PD necessitates a multidisciplinary team.
  • The primary goal is to enhance patient and family quality of life, sometimes prioritizing it over complete motor symptom relief.
  • A balanced approach addressing motor, non-motor, and pharmacologic aspects is crucial.